Technical Analysis for IFRX - InflaRx N.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| 20 DMA Support | Bullish | 1.94% | |
| 200 DMA Support | Bullish | 1.94% | |
| 50 DMA Support | Bullish | 1.94% | |
| Bollinger Band Squeeze | Range Contraction | 1.94% | |
| Outside Day | Range Expansion | 1.94% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.64% |
| Alert | Time |
|---|---|
| 200 DMA Support | about 19 hours ago |
| 10 DMA Resistance | about 22 hours ago |
| 20 DMA Support | about 24 hours ago |
| 50 DMA Support | about 24 hours ago |
| Rose Above 10 DMA | about 24 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/08/2024
InflaRx N.V. Description
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Immune System Autoimmune Disease Clinical Development Antibodies Monoclonal Antibodies Monoclonal Antibody Inflammatory Diseases Complement System Hidradenitis Suppurativa C5a
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.1 |
| 52 Week Low | 1.14 |
| Average Volume | 74,248 |
| 200-Day Moving Average | 1.53 |
| 50-Day Moving Average | 1.53 |
| 20-Day Moving Average | 1.53 |
| 10-Day Moving Average | 1.56 |
| Average True Range | 0.09 |
| RSI (14) | 55.36 |
| ADX | 16.71 |
| +DI | 15.59 |
| -DI | 20.06 |
| Chandelier Exit (Long, 3 ATRs) | 1.44 |
| Chandelier Exit (Short, 3 ATRs) | 1.70 |
| Upper Bollinger Bands | 1.61 |
| Lower Bollinger Band | 1.45 |
| Percent B (%b) | 0.79 |
| BandWidth | 10.39 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.01 |
| MACD Histogram | 0.0035 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.70 | ||||
| Resistance 3 (R3) | 1.69 | 1.65 | 1.68 | ||
| Resistance 2 (R2) | 1.65 | 1.62 | 1.65 | 1.67 | |
| Resistance 1 (R1) | 1.61 | 1.60 | 1.63 | 1.62 | 1.67 |
| Pivot Point | 1.57 | 1.57 | 1.58 | 1.57 | 1.57 |
| Support 1 (S1) | 1.53 | 1.54 | 1.55 | 1.54 | 1.49 |
| Support 2 (S2) | 1.49 | 1.52 | 1.49 | 1.49 | |
| Support 3 (S3) | 1.45 | 1.49 | 1.48 | ||
| Support 4 (S4) | 1.46 |
